Elevated expression of WSB2 degrades p53 and activates the IGFBP3-AKT-mTOR-dependent pathway to drive hepatocellular carcinoma
0
조회
0
다운로드
0
인용
0
참고문헌
초록
Dysregulation of wild-type p53 turnover is a key cause of hepatocellular carcinoma (HCC), yet its mechanism remains poorly understood. Here, we report that WD repeat and SOCS box containing protein 2 (WSB2), an E3 ubiquitin ligase, is an independent adverse prognostic factor in HCC patients. WSB2 drives HCC tumorigenesis and lung metastasis in vitro and in vivo. Mechanistically, WSB2 is a new p53 destabilizer that promotes K48-linked p53 polyubiquitination at the Lys291 and Lys292 sites in HCC cells, leading to p53 proteasomal degradation. Degradation of p53 causes IGFBP3-dependent AKT/mTOR signaling activation. Furthermore, WSB2 was found to bind to the p53 tetramerization domain via its SOCS box domain. Targeting mTOR with everolimus, an oral drug, significantly blocked WSB2-triggered HCC tumorigenesis and metastasis in vivo. In clinical samples, high expression of WSB2 was associated with low wild-type p53 expression and high p-mTOR expression. These findings demonstrate that WSB2 is overexpressed and degrades wild-type p53 and then activates the IGFBP3-AKT/mTOR axis, leading to HCC tumorigenesis and lung metastasis, which indicates that targeting mTOR could be a new therapeutic strategy for HCC patients with high WSB2 expression and wild-type p53.
Abstract
Dysregulation of wild-type p53 turnover is a key cause of hepatocellular carcinoma (HCC), yet its mechanism remains poorly understood. Here, we report that WD repeat and SOCS box containing protein 2 (WSB2), an E3 ubiquitin ligase, is an independent adverse prognostic factor in HCC patients. WSB2 drives HCC tumorigenesis and lung metastasis in vitro and in vivo. Mechanistically, WSB2 is a new p53 destabilizer that promotes K48-linked p53 polyubiquitination at the Lys291 and Lys292 sites in HCC cells, leading to p53 proteasomal degradation. Degradation of p53 causes IGFBP3-dependent AKT/mTOR signaling activation. Furthermore, WSB2 was found to bind to the p53 tetramerization domain via its SOCS box domain. Targeting mTOR with everolimus, an oral drug, significantly blocked WSB2-triggered HCC tumorigenesis and metastasis in vivo. In clinical samples, high expression of WSB2 was associated with low wild-type p53 expression and high p-mTOR expression. These findings demonstrate that WSB2 is overexpressed and degrades wild-type p53 and then activates the IGFBP3-AKT/mTOR axis, leading to HCC tumorigenesis and lung metastasis, which indicates that targeting mTOR could be a new therapeutic strategy for HCC patients with high WSB2 expression and wild-type p53.
참고문헌 (50)
- Sung, H., "Global Cancer Statistics 2020 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J. Clin, 71, pp.209~249 (2021)
- Moon, A. M., "Contemporary epidemiology of chronic liver disease and Cirrhosis", Clin. Gastroenterol. Hepatol, 18, pp.2650~2666 (2020)
- Yuan, J. H., "The MBNL3 splicing factor promotes hepatocellular carcinoma by increasing PXN expression through the alternative splicing of lncRNA-PXN-AS1", Nat. Cell Biol, 19, pp.820~832 (2017)
- Levine, A. J., "The first 30 years of p53 : growing ever more complex", Nat. Rev. Cancer, 9, pp.749~758 (2009)
- Kastenhuber, E. R., "Putting p53 in context", Cell, 170, pp.1062~1078 (2017)
- Donehower, L. A., "Integrated analysis of TP53 gene and pathway alterations in the Cancer Genome Atlas", Cell Rep, 28, pp.1370~1384 (2019)
- Dai, C., "p53 post-translational modification : deregulated in tumorigen esis", Trends Mol. Med, 16, pp.528~536 (2010)
- Hafner, A., "The multiple mechanisms that regulate p53 activity and cell fate", Nat. Rev. Mol. Cell Biol, 20, pp.199~210 (2019)
- Deng, L., "The role of ubiquitination in tumorigenesis and targeted drug discovery", Signal Transduct. Target Ther, 5, pp.11~ (2020)
- Mansour, M. A., "Ubiquitination : Friend and foe in cancer", Int J. Biochem Cell Biol, 101, pp.80~93 (2018)
- Berndsen, C. E., "New insights into ubiquitin E3 ligase mechanism", Nat. Struct. Mol. Biol, 21, pp.301~307 (2014)
- Linossi, E. M., "The SOCS box-adapting proteins for ubiquitination and proteasomal degradation", IUBMB life, 64, pp.316~323 (2012)
- Zhou, Z., "TRIM59 is up-regulated in gastric tumors, promoting ubiquitination and degradation of p53", Gastroenterology, 147, pp.1043~1054 (2014)
- Kubbutat, M. H., "Regulation of p53 stability by Mdm2", Nature, 387, pp.299~303 (1997)
- Yu, L., "Thirty-plus functional families from a single motif", Protein Sci. Publ. Protein Soc, 9, pp.2470~2476 (2000)
- Tong, Y., "HIF1 regulates WSB-1 expression to promote hypoxia-induced chemoresistance in hepatocellular carcinoma cells", FEBS Lett, 587, pp.2530~2535 (2013)
- Tang, Z., "Safflower yellow promotes angiogenesis through p-VHL", HIF-1α, Biomed. Pharmacother, pp.2018, 107[DOI]
- Zhang, Y., "WD repeat and SOCS box containing protein 2 in the proliferation, cycle progression, and migration of melanoma cells", Biomed. Pharmacother, 116, pp.108974~ (2019)
- Ma, L., "miR-28-5p inhibits the migration of breast cancer by regulating WSB2", Int J. Mol. Med, 46, pp.1562~1570 (2020)
- EASL. Clinical Practice Guidelines, "Management of hepatocellular carcinoma", J. Hepatol, 69, pp.182~236 (2018)
- Lin, X. T., "Elevated FBXO45 promotes liver tumorigenesis through enhancing IGF2BP1 ubiquitination and subsequent PLK1 upregulation", eLife, 10, pp.e70715~ (2021)
- Liang, J., "Non-coding small nucleolar RNA SNORD17 promotes the pro gression of hepatocellular carcinoma through a positive feedback loop upon p53inactivation", Cell Death Differ, 29, pp.988~1003 (2022)
- Yuan, H., "HBx represses WDR77 to enhance HBV replication by DDB1mediated WDR77 degradation in the liver", Theranostics, 11, pp.8362~8378 (2021)
- Li, R., "E3 ligase ASB8 promotes porcine reproductive and respiratory syn drome virus proliferation by stabilizing the viral Nsp1α protein and degrading host IKKβ kinase", Virology, 532, pp.55~68 (2019)
- Hershko, A., "The ubiquitin system", Ann. Rev. Biochem, 67, pp.425~479 (1998)
- Lei, C. Q., "USP19 inhibits TNF-αand IL-1β-triggered NF-κB activation by Deubiquitinating TAK1", J. immunol, 203, pp.259~268 (2019)
- Begun, J., "Integrated genomics of Crohn’s disease risk variant identifies a role for CLEC12A in antibacterial autophagy", Cell Rep, 11, pp.1905~1918 (2015)
- Lee, E. W., "Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell cycle arrest and apoptosis", EMBO J, 28, pp.2100~2113 (2009)
- Harper, J. W., "Neddylating the guardian; Mdm2 catalyzed conjugation of Nedd8 to p53", Cell, 118, pp.2~4 (2004)
- Feng, Z., "p53 regulation of the IGF-1", AKT, Cold Spring Harb. Perspect. Biol, pp.2010, 2[DOI]
- Buckbinder, L., "Induction of the growth inhibitor IGF-binding protein 3 by p53", Nature, 377, pp.646~649 (1995)
- Houghton, P. J., "Everolimus", Clin. Cancer Res, 16, pp.1368~1372 (2010)
- Baselga, J., "Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer", N. Engl. J. Med, 366, pp.520~529 (2012)
- Liu, M., "The genetic and epigenetic alterations in human hepatocellular carcinoma : a recent update", Protein Cell, 5, pp.673~691 (2014)
- Xiong, H. J., "Elevated FBXL6 activates both wild-type KRAS and mutant KRASG12D and drives HCC tumorigenesis via the ERK", mTOR, ROS axis in mice, pp.Mil. Med Res, 2023[DOI]
- Zheng, N., "Ubiquitin ligases: structure, function, and regulation", Ann. Rev. Biochem, 86, pp.129~157 (2017)
- Luo, Y. D., "p53 haploinsufficiency and increased mTOR signalling define a subset of aggressive hepatocellular carcinoma", J. Hepatol, 74, pp.96~108 (2021)
- Green, D. R., "Cytoplasmic functions of the tumour suppressor p53", Nature, 458, pp.1127~1130 (2009)
- Levine, A. J., "p53 : 800 million years of evolution and 40 years of discovery", Nat. Rev. Cancer, 20, pp.471~480 (2020)
- Vassilev, L. T., "In vivo activation of the p53 pathway by small-molecule antagonists of MDM2", Science, 303, pp.844~848 (2004)
- Panka, D. J., "EffectsofHDM2antagonismon sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+", Gr-1+ myeloid derived suppressor cells, 2013, pp.12, 17~
- Bourdon, J. C., "Further characterisation of the p53 responsive element identification of new candidate genes for trans-activation by p53", Oncogene, 14, pp.85~94 (1997)
- Cai, Q., "IGFBP-3", IGFBP-3 receptor system as an anti-tumor and anti-metastatic signaling in cancer, 2020, pp.9, 1261~
- Matter, M. S., "Targeting the mTOR pathway in hepatocellular carcinoma : current state and future trends", J. Hepatol, 60, pp.855~865 (2014)
- Yamanaka, K., "Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma––systematic review and meta-analysis", Cancer Med, 2, pp.862~871 (2013)
- Yao, J. C., "Everolimus for advanced pancreatic neuroendocrine tumors", N. Engl. J. Med, 364, pp.514~523 (2011)
- Zhu, A. X., "Phase 1", 2 study of everolimus in advanced hepatocellular car cinoma, 2011, pp.117, 5094~5102
- Yan, X., "Sirolimus or Everolimus improves survival after liver transplantation for hepatocellular carcinoma : a systematic review and meta-analysis", Liver Transpl, 28, pp.1063~1077 (2022)
- Choi, H. J., "Combining Everolimus and Ku0063794 promotes apoptosis of hepatocellular carcinoma cells via reduced autophagy resulting from diminished expression of miR-4790-3p", Int J. Mol. Sci, 22, pp.2859~ (2021)
- Kong, N., "Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53-deficient cancers to mTOR inhibition", Sci. Transl. Med, 11, pp.eaaw1565~ (2019)